Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project studyF Boccardo, A Rubagotti, M Barichello, et al.
Bioorganic & Medicinal Chemistry|December 16, 2018
Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitorsCyril Barinka, Zora Novakova, Niyada Hin, et al.
Cell Metabolism|February 14, 2012
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue typeMariia O Yuneva, Teresa W M Fan, Thaddeus D Allen, et al.
Cancer Research|November 4, 2010
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1Meghan J Seltzer, Bryson D Bennett, Avadhut D Joshi, et al.
Journal of Medicinal Chemistry|May 31, 2012
Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffoldsDoris Stoermer, Dilrukshi Vitharana, Niyada Hin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancerF Boccardo, A Rubagotti, M Battaglia, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Identification of a series of pyrrolo-pyrimidine based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replicationJessica J Pfannenstiel, Men Thi Hoai Duong, Daniel Cluff, et al.
Mbio|May 23, 2025
Identification of a series of pyrrolo-pyrimidine-based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replicationJessica J Pfannenstiel, Men Thi Hoai Duong, Daniel Cluff, et al.
MMWR. Morbidity and Mortality Weekly Report|March 17, 2022
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022Ashley L Fowlkes, Sarang K Yoon, Karen Lutrick, et al.
Pageof 7